• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc. (Amendment)

    11/9/23 5:24:48 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BDTX alert in real time by email
    SC 13D/A 1 d473224dsc13da.htm SC 13D/A SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Rule 13d-102)

     

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

    (Amendment No. 5)*

    Black Diamond Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    09203E105

    (CUSIP Number)

    Versant Venture Capital VI, L.P.

    Max Eisenberg

    One Sansome Street, Suite 1650

    San Francisco, CA 94104

    415-801-8100

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 11, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Venture Capital VI, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      3,947,941 shares of common stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      3,947,941 shares of common stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,947,941 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      7.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by Versant Venture Capital VI, L.P. (“Versant VI”), Versant Voyageurs I Parallel, L.P. (“Versant I Parallel”), Versant Voyageurs I, L.P. (“Versant Voyageurs I”), Versant Vantage I, L.P. (“Versant Vantage I”), Versant Ventures VI GP, L.P. (“Versant Ventures VI GP”), Versant Ventures VI GP-GP, LLC (“Versant Ventures VI GP-GP”), Versant Voyageurs I GP, L.P. (“Versant Voyageurs I GP LP”), Versant Voyageurs I GP Company (“Versant Voyageurs I GP”), Versant Vantage I GP, L.P. (“Versant Vantage I GP LP”) and Versant Vantage I GP-GP, LLC (“Versant Vantage I GP-GP” and, with Versant VI, Versant I Parallel, Versant Voyageurs I, Versant Vantage I, Versant Ventures VI GP, Versant Ventures VI GP-GP, Versant Voyageurs I GP LP, Versant Voyageurs I GP, and Versant Vantage I GP LP, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Issuer’s quarterly report on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on August 11, 2023 (the “Form 10-Q”).


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      4,328,883 shares of common stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      4,328,883 shares of common stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,328,883 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      8.4% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    Includes (i) 3,947,941 shares held by Versant VI and (ii) 380,942 shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI and Versant I Parallel.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Ventures VI GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      4,328,883 shares of common stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      4,328,883 shares of common stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      4,328,883 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      8.4% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    Includes (i) 3,947,941 shares held by Versant VI and (ii) 380,942 shares held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP share voting and dispositive power with respect to the shares held by Versant VI and Versant I Parallel.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Voyageurs I Parallel, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Ontario Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      380,942 shares of common stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      380,942 shares of common stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      380,942 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      0.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Each of Versant Voyageurs I GP LP, Versant Ventures VI GP and Versant Ventures VI GP-GP share voting and dispositive power with respect to the shares held by Versant I Parallel.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Voyageurs I GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      380,942 shares of common stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      380,942 shares of common stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      380,942 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      0.7% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant I Parallel. Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Each of Versant Voyageurs I GP LP, Versant Ventures VI GP and Versant Ventures VI GP-GP share voting and dispositive power with respect to the shares held by Versant I Parallel.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Voyageurs I, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Ontario Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      1,277,541 shares of common stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      1,277,541 shares of common stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,277,541 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      2.5% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant Voyageurs I. Versant Voyageurs I GP is the general partner of Versant Voyageurs I and shares voting and dispositive power with respect to the shares held by Versant Voyageurs I.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Voyageurs I GP Company

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Nova Scotia, Canada

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      1,277,541 shares of common stock (2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      1,277,541 shares of common stock (2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,277,541 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      2.5% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant Voyageurs I. Versant Voyageurs I GP is the general partner of Versant Voyageurs I and shares voting and dispositive power with respect to the shares held by Versant Voyageurs I.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage I, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      WC

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      822,140 shares of common stock (2)

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      822,140 shares of common stock (2)

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      822,140 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      1.6% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant Vantage I. Versant Vantage I GP LP is the general partner of Versant Vantage I and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Each of Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage I.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage I GP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      822,140 shares of common stock(2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      822,140 shares of common stock(2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      822,140 shares of common stock (2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      1.6% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant Vantage I. Versant Vantage I GP LP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Each of Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage I.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

      1.    

      Name of Reporting Persons

     

      Versant Vantage I GP-GP, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☒(1)

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      AF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0

         8.   

      Shared Voting Power

     

      822,140 shares of common stock(2)

         9.   

      Sole Dispositive Power

     

      0

       10.   

      Shared Dispositive Power

     

      822,140 shares of common stock(2)

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      822,140 shares of common stock(2)

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row 11

     

      1.6% (3)

    14.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)

    These shares are held by Versant Vantage I. Versant Vantage I GP LP is the general partner of Versant Vantage I, and Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. Each of Versant Vantage I GP LP and Versant Vantage I GP-GP share voting and dispositive power with respect to the shares held by Versant Vantage I.

    (3)

    The percentages used herein are calculated based upon 51,575,323 shares issued and outstanding as of August 1, 2023 as set forth in the Form 10-Q.


    CUSIP No. 09203E105    13D   

     

    Explanatory Note:

    This Amendment No. 5 (“Amendment”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission (the “Commission”) on February 13, 2020, as amended by Amendment No. 1 filed with the Commission on August 21, 2020, Amendment No. 2 filed with the Commission on September 25, 2020, Amendment No. 3 filed with the Commission on November 23, 2020, and Amendment No. 4 filed with the Commission on December 3, 2020 (collectively, the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 1. Security and Issuer

    The address of the principal executive offices of the Issuer is One Main Street, 14th Floor, Cambridge, MA 02142.

    Item 2. Identity and Background

    (b) The principal business and principal business office of the Reporting Persons is Versant Ventures, One Sansome Street, Suite 1650, San Francisco, CA 94104.

    Item 5. Interest in Securities of the Issuer

    This information reported below is based on a total of 51,575,323 shares of the Issuer’s Common Stock outstanding as of August 1, 2023, as reported on the Issuer’s Form 10-Q filed with the Commission on August 11, 2023. This Amendment No. 5 is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D. Such transactions resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D.

    (a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    November 9, 2023
    Versant Venture Capital VI, L.P.
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Ventures VI GP, L.P.
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Ventures VI GP-GP, LLC
    By:  

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Voyageurs I Parallel, L.P.
    By:   Versant Voyageurs I GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner
    By:  

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Voyageurs I GP, L.P.
    By:   Versant Ventures VI GP, L.P.
    Its:   General Partner
    By:   Versant Ventures VI GP-GP, LLC
    Its:   General Partner

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Voyageurs I, L.P.
    By:   Versant Voyageurs I GP Company
    Its:   General Partner

    /s/ Max Eisenberg, Chief Operating Officer


    Versant Voyageurs I GP Company

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Vantage I, L.P.
    By:   Versant Vantage I GP, L.P.
    Its:   General Partner
    By:   Versant Vantage I GP-GP, LLC
    Its:   General Partner

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Vantage I GP, L.P.
    By:   Versant Vantage I GP-GP, LLC
    Its:   General Partner

    /s/ Max Eisenberg, Chief Operating Officer

    Versant Vantage I GP-GP, LLC

    /s/ Max Eisenberg, Chief Operating Officer

    Get the next $BDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDTX

    DatePrice TargetRatingAnalyst
    7/31/2024$20.00Outperform
    Raymond James
    7/14/2023Overweight
    Piper Sandler
    6/30/2023$2.00 → $10.00Hold → Buy
    Stifel
    6/28/2023$11.00Neutral → Buy
    H.C. Wainwright
    6/27/2023$10.00Neutral → Outperform
    Wedbush
    3/29/2022Outperform → Neutral
    Wedbush
    3/22/2022Buy → Neutral
    H.C. Wainwright
    9/30/2021$10.00Hold
    Stifel
    More analyst ratings

    $BDTX
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Black Diamond Therapeutics Inc.

      DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      4/18/25 4:05:01 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Black Diamond Therapeutics Inc.

      DEF 14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      4/18/25 4:01:26 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Black Diamond Therapeutics Inc.

      SCHEDULE 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      3/21/25 1:01:32 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $BDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $BDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

      SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 1:28:32 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

      SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 12:02:05 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

      SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      8/8/24 4:48:56 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Behbahani Ali was granted 7,646 shares, increasing direct ownership by 12% to 70,980 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:19:30 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Raman Prakash was granted 6,848 shares, increasing direct ownership by 68% to 16,993 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:04:02 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Biotech Growth N V sold $11,997,749 worth of shares (5,784,292 units at $2.07), decreasing direct ownership by 68% to 2,733,547 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/20/25 9:01:40 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025 Webcasts will be available at the start of the presentations on the investor rel

      3/31/25 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

      The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF alterations, in solid tumors, including non-small cell lung cancerBlack Diamond will receive an upfront payment of $70 million and up to $710 million in development and commercial sales milestone payments plus royalties SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a

      3/19/25 7:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025Cash, cash equivalents, and investments of $98.6 million as of December 31, 2024, expected to be sufficient to fund operations into Q4 2026 CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the fourth quarter an

      3/6/25 4:01:00 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James initiated coverage on Black Diamond Therapeutics with a new price target

      Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00

      7/31/24 6:19:23 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Black Diamond Therapeutics

      Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight

      7/14/23 7:42:17 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously

      6/30/23 7:17:14 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Financials

    Live finance-specific insights

    See more
    • Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

      BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i

      6/27/23 7:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      10/19/23 3:08:35 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Black Diamond Therapeutics Announces Changes to Board of Directors

      CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog

      4/11/24 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir

      11/6/23 7:45:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care